Exciting news in the med-tech world!
🎉Capstan Medical, a Santa Cruz-based innovator in robotic-enabled minimally invasive solutions for heart valve disease, has just secured an impressive $110 million in Series C funding.
This oversubscribed round, led by Eclipse, will propel Capstan's mission to revolutionize structural heart treatments.
Key highlights:
- Capstan's technology combines novel heart valve implants, advanced catheter technology, and a robotic platform to address limitations in current treatment options.
- The funding will support expanded clinical and development work, paving the way for upcoming pivotal trials.
- With over 7 million people in the U.S. affected by heart valve disease, Capstan's solution aims to treat a broader set of patients who currently lack viable option.
CEO Maggie Nixon emphasizes the potential of percutaneous intervention to dramatically increase treatment options for millions suffering from heart valve disease. This breakthrough could be a game-changer in combating the world's leading cause of death.
Kudos to Capstan Medical for their innovative approach and to the investors supporting this critical mission!
#MedTech #HeartHealth #Innovation #RoboticSurgery
Founder and Senior Managing Director of BioStar Capital and BioStar Ventures II, III, IV and V Interventional cardiologist Venture capitalist
1moShockwave revolutionized vascular lithotripsy for so many patients in need —— but it is time for a better, easier, less traumatic and more dependable approach — with modern day AI built in to so many features . Just wait ! Nice job team . Making BioStar proud 😎💪